<DOC>
	<DOCNO>NCT00045201</DOCNO>
	<brief_summary>Phase I trial study effectiveness combine erlotinib hydrochloride irinotecan hydrochloride treat patient advance solid tumor . Erlotinib hydrochloride may stop growth tumor cell block enzymes necessary tumor cell growth . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining erlotinib hydrochloride chemotherapy may kill tumor cell .</brief_summary>
	<brief_title>Erlotinib Hydrochloride Irinotecan Hydrochloride Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) erlotinib ( erlotinib hydrochloride ) irinotecan ( irinotecan hydrochloride ) , relation presence absence UGT1A1*28 polymorphism , patient advance solid tumor overexpress epidermal growth factor receptor . II . Determine dose-limiting toxicity regimens patient . III . Determine whether erlotinib alters disposition irinotecan use previously describe limited sample model . IV . Determine factor influence disposition drug , include genetic variation UGT1A1 BCRP , patient treat regimen . V. Determine factor influence disposition drug , term tumor BCRP-expression , tumor sample patient treat drug MTD . VI . Evaluate effect regimen epidermal growth factor receptor phosphorylation patient . VII . Assess , preliminarily , antitumor activity patient treat regimen . VIII . Correlate , preliminarily , EGFR phosphorylation and/or BCRP -expression response tumor sample patient . OUTLINE : This dose-escalation study . Patients stratify accord UGTA1A genotype ( patient regardless genotype [ close accrual 9/15/04 ] v UGT1A1 6/6 genotype v UGTA1A 6/7 7/7 genotype ) . Patients receive oral erlotinib hydrochloride daily day -6 -1 . Patients receive irinotecan hydrochloride intravenously ( IV ) 90 minute day 1 oral erlotinib daily day 1-21 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient per stratum receive escalate dos erlotinib hydrochloride irinotecan hydrochloride MTD determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Additional patient treat MTD . Patients follow 3 month .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically confirm malignancy overexpresses epidermal growth factor receptor ( EGFR ) Unresectable disease know standard therapy ispotentially curative definitely capable extend life expectancy UGT1A1 genotype 6/6 , 6/7 , 7/7 Willing provide biologic specimens Lesions amenable 2 biopsy tumor site ( patient receive MTD group 2 3 ) No know brain metastasis Performance status ECOG 02 At least 12 week Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9.0 g/dL Bilirubin great 1.5 time upper limit normal ( ULN ) AST ≤ 2.5 time ULN ( 5 time ULN liver metastasis present ) Creatinine great 1.5 time ULN No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No New York Heart Association class III IV heart disease No gastrointestinal tract disease result inability take oral nasogastric medication No requirement IV alimentation No active peptic ulcer disease No abnormalities cornea ( e.g. , dry eye syndrome Sjögren 's syndrome ) No congenital abnormality ( e.g. , Fuch 's dystrophy ) No abnormal slitlamp examination use vital dye ( e.g. , fluorescein BengalRose ) No abnormal corneal sensitivity test ( e.g. , Schirmer test similar tear production test ) No uncontrolled concurrent illness No ongoing active infection No significant traumatic injury within past 21 day No seizure disorder No psychiatric illness social situation would preclude study compliance Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent grapefruit grapefruit juice No smoking study More 4 week since prior immunotherapy biologic therapy No concurrent immunotherapy More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No concurrent chemotherapy Not specify More 4 week since prior radiotherapy No prior radiotherapy 25 % bone marrow No concurrent radiotherapy More 3 week since prior major surgery No prior surgical procedure affect absorption No prior EGFRtargeting therapy ( e.g. , gefitinib EKB569 ) No concurrent investigational therapy No concurrent enzymeinducing anticonvulsant ( e.g. , phenytoin , phenobarbital , carbamazepine , valproic acid ) No concurrent combination antiretroviral therapy HIVpositive patient No concurrent enrollment another study involve pharmacological agent symptom control therapeutic intent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>